Therapeutic dilemmas in patients with symptomatic polycystic liver disease

R. H. Turnage, Frederic Eckhauser, J. A. Knol, N. W. Thompson

Research output: Contribution to journalArticle

Abstract

Most reports of the operative treatment of symptomatic polycystic liver disease (PCLD) are anecdotal or consist of only a small subset of patients in an institution's overall experience treating hepatic cysts. We have reviewed our experience with nine consecutive patients with symptomatic PCLD undergoing operative treatment from 1981 to 1987. Indications for operation include chronic abdominal pain (4 patients), cyst infection (2 patients), biliary obstruction (2 patients), inferior vena cava obstruction (2 patients), and symptomatic abdominal distention (2 patients). The average duration of symptoms leading to operation was 7.8 months. Three types of cystic disease were identified based on gross morphology: dominant cystic disease (3 patients), diffuse cystic disease (4 patients), and mixed cystic disease (2 patients). Operations to treat symptomatic PCLD included unroofing and external drainage of infected cysts (2 operations), simple unroofing (1 operation), cyst fenestration alone (4 operations) and fenestration combined with resection (3 operations). Treatment directed at principally dominant cysts (five patients) was associated with resolution of symptoms and low morbidity and mortality. Treatment directed at diffusely cystic disease (four patients) resulted in significant morbidity and mortality including three deaths. Successful surgical treatment of symptomatic patients with PCLD depends on accurate preoperative identification of patients with symptoms related to one or more dominant cysts. In this setting fenestration or simple unroofing of the dominant cyst is safe and effective treatment. By comparison, extensive fenestration with or without hepatic resection in patients with symptoms attributed to a diffusely cystic liver may be associated with unacceptable morbidity and mortality. One must carefully weigh the risks versus the potential benefits of extensive hepatic surgery in patients with symptomatic PCLD. This is particularly true for the patient whose sole complaint is chronic abdominal pain.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalAmerican Surgeon
Volume54
Issue number6
StatePublished - 1988
Externally publishedYes

Fingerprint

Cysts
Therapeutics
Polycystic liver disease
Liver
Morbidity
Mortality
Inferior Vena Cava
Drainage
Infection

ASJC Scopus subject areas

  • Surgery

Cite this

Turnage, R. H., Eckhauser, F., Knol, J. A., & Thompson, N. W. (1988). Therapeutic dilemmas in patients with symptomatic polycystic liver disease. American Surgeon, 54(6), 365-372.

Therapeutic dilemmas in patients with symptomatic polycystic liver disease. / Turnage, R. H.; Eckhauser, Frederic; Knol, J. A.; Thompson, N. W.

In: American Surgeon, Vol. 54, No. 6, 1988, p. 365-372.

Research output: Contribution to journalArticle

Turnage, RH, Eckhauser, F, Knol, JA & Thompson, NW 1988, 'Therapeutic dilemmas in patients with symptomatic polycystic liver disease', American Surgeon, vol. 54, no. 6, pp. 365-372.
Turnage, R. H. ; Eckhauser, Frederic ; Knol, J. A. ; Thompson, N. W. / Therapeutic dilemmas in patients with symptomatic polycystic liver disease. In: American Surgeon. 1988 ; Vol. 54, No. 6. pp. 365-372.
@article{243aa002fb384b9bb704d2793d44e0a0,
title = "Therapeutic dilemmas in patients with symptomatic polycystic liver disease",
abstract = "Most reports of the operative treatment of symptomatic polycystic liver disease (PCLD) are anecdotal or consist of only a small subset of patients in an institution's overall experience treating hepatic cysts. We have reviewed our experience with nine consecutive patients with symptomatic PCLD undergoing operative treatment from 1981 to 1987. Indications for operation include chronic abdominal pain (4 patients), cyst infection (2 patients), biliary obstruction (2 patients), inferior vena cava obstruction (2 patients), and symptomatic abdominal distention (2 patients). The average duration of symptoms leading to operation was 7.8 months. Three types of cystic disease were identified based on gross morphology: dominant cystic disease (3 patients), diffuse cystic disease (4 patients), and mixed cystic disease (2 patients). Operations to treat symptomatic PCLD included unroofing and external drainage of infected cysts (2 operations), simple unroofing (1 operation), cyst fenestration alone (4 operations) and fenestration combined with resection (3 operations). Treatment directed at principally dominant cysts (five patients) was associated with resolution of symptoms and low morbidity and mortality. Treatment directed at diffusely cystic disease (four patients) resulted in significant morbidity and mortality including three deaths. Successful surgical treatment of symptomatic patients with PCLD depends on accurate preoperative identification of patients with symptoms related to one or more dominant cysts. In this setting fenestration or simple unroofing of the dominant cyst is safe and effective treatment. By comparison, extensive fenestration with or without hepatic resection in patients with symptoms attributed to a diffusely cystic liver may be associated with unacceptable morbidity and mortality. One must carefully weigh the risks versus the potential benefits of extensive hepatic surgery in patients with symptomatic PCLD. This is particularly true for the patient whose sole complaint is chronic abdominal pain.",
author = "Turnage, {R. H.} and Frederic Eckhauser and Knol, {J. A.} and Thompson, {N. W.}",
year = "1988",
language = "English (US)",
volume = "54",
pages = "365--372",
journal = "American Surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "6",

}

TY - JOUR

T1 - Therapeutic dilemmas in patients with symptomatic polycystic liver disease

AU - Turnage, R. H.

AU - Eckhauser, Frederic

AU - Knol, J. A.

AU - Thompson, N. W.

PY - 1988

Y1 - 1988

N2 - Most reports of the operative treatment of symptomatic polycystic liver disease (PCLD) are anecdotal or consist of only a small subset of patients in an institution's overall experience treating hepatic cysts. We have reviewed our experience with nine consecutive patients with symptomatic PCLD undergoing operative treatment from 1981 to 1987. Indications for operation include chronic abdominal pain (4 patients), cyst infection (2 patients), biliary obstruction (2 patients), inferior vena cava obstruction (2 patients), and symptomatic abdominal distention (2 patients). The average duration of symptoms leading to operation was 7.8 months. Three types of cystic disease were identified based on gross morphology: dominant cystic disease (3 patients), diffuse cystic disease (4 patients), and mixed cystic disease (2 patients). Operations to treat symptomatic PCLD included unroofing and external drainage of infected cysts (2 operations), simple unroofing (1 operation), cyst fenestration alone (4 operations) and fenestration combined with resection (3 operations). Treatment directed at principally dominant cysts (five patients) was associated with resolution of symptoms and low morbidity and mortality. Treatment directed at diffusely cystic disease (four patients) resulted in significant morbidity and mortality including three deaths. Successful surgical treatment of symptomatic patients with PCLD depends on accurate preoperative identification of patients with symptoms related to one or more dominant cysts. In this setting fenestration or simple unroofing of the dominant cyst is safe and effective treatment. By comparison, extensive fenestration with or without hepatic resection in patients with symptoms attributed to a diffusely cystic liver may be associated with unacceptable morbidity and mortality. One must carefully weigh the risks versus the potential benefits of extensive hepatic surgery in patients with symptomatic PCLD. This is particularly true for the patient whose sole complaint is chronic abdominal pain.

AB - Most reports of the operative treatment of symptomatic polycystic liver disease (PCLD) are anecdotal or consist of only a small subset of patients in an institution's overall experience treating hepatic cysts. We have reviewed our experience with nine consecutive patients with symptomatic PCLD undergoing operative treatment from 1981 to 1987. Indications for operation include chronic abdominal pain (4 patients), cyst infection (2 patients), biliary obstruction (2 patients), inferior vena cava obstruction (2 patients), and symptomatic abdominal distention (2 patients). The average duration of symptoms leading to operation was 7.8 months. Three types of cystic disease were identified based on gross morphology: dominant cystic disease (3 patients), diffuse cystic disease (4 patients), and mixed cystic disease (2 patients). Operations to treat symptomatic PCLD included unroofing and external drainage of infected cysts (2 operations), simple unroofing (1 operation), cyst fenestration alone (4 operations) and fenestration combined with resection (3 operations). Treatment directed at principally dominant cysts (five patients) was associated with resolution of symptoms and low morbidity and mortality. Treatment directed at diffusely cystic disease (four patients) resulted in significant morbidity and mortality including three deaths. Successful surgical treatment of symptomatic patients with PCLD depends on accurate preoperative identification of patients with symptoms related to one or more dominant cysts. In this setting fenestration or simple unroofing of the dominant cyst is safe and effective treatment. By comparison, extensive fenestration with or without hepatic resection in patients with symptoms attributed to a diffusely cystic liver may be associated with unacceptable morbidity and mortality. One must carefully weigh the risks versus the potential benefits of extensive hepatic surgery in patients with symptomatic PCLD. This is particularly true for the patient whose sole complaint is chronic abdominal pain.

UR - http://www.scopus.com/inward/record.url?scp=0023923091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023923091&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 365

EP - 372

JO - American Surgeon

JF - American Surgeon

SN - 0003-1348

IS - 6

ER -